C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
SciVario® twin Bioprocess Controller: Addressing Current and Future Needs
Increasing the efficiency of bioprocess workflows is key to stay competitive. The SciVario twin helps to develop and optimize processes in terms of time and cost efficiency. All critical process parameters can be precisely controlled directly at the controller’s touch screen. Regardless of the research segment, it is suitable for microbial and cell culture applications. The innovative bay-drawer system enables the system to flexibly adapt to unique requirements and changing processes. Eppendorf will offer updates with new functional modules, support for more, larger bioreactors, and additional software features to make the SciVario twin a future-proof solution.
Next-gen COVID-19 vaccine good in preclinical tests
Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
EMA: AZD1222 causes serious rare ADEs
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
Trading medical cannabis in Europe
The regulatory situation regarding the trade of medicinal cannabis currently varies enormously from country to country within the European Union. Unfortunately, there is still no full regulatory harmonization on a European level.
Targeting SARS-CoV-2 differently
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus’ main protease.
miRNAs unmask vulnerability in breast cancer stem cells
Researchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Advancing protein production with Pichia pastoris
Effective bioprocess development starts with the targeted and time-saving generation of high-productivity strains already considering economic target values and regulatory requirements. The UNLOCK PICHIA technology platform comprises a large number of versatile expression tools for the generation and identification of effective industrial protein production strains without compromising development timelines.
Janssen to pledge COVID-19 vaccine to African Union
Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
A bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.